New Data Show Investigational Compound Dapagliflozin When Added To Glimepiride Maintained Reductions In Blood Sugar Levels In Adults With Type 2 Diabetes Over 48 Weeks Of Treatment
Hypoglycemic events were more frequent in the dapagliflozin groups (9.7% in 2.5 mg group, 10.3% in 5 mg group, 11.3% in 10 mg group) compared to the placebo group (6.8%), with no patients discontinuing treatment due to hypoglycemia. There was one major episode of hypoglycemia in the dapagliflozin 2.5 mg group.
The percentage of patients with events suggestive of genital infections was higher for dapagliflozin added to glimepiride compared to placebo added to glimepiride, as follows: 5.2% with dapagliflozin 2.5 mg, 6.2% with dapagliflozin 5 mg and 8.6% for dapagliflozin 10 mg compared to 1.4% with placebo added to glimepiride. Overall, events suggestive of genital infections were higher in females than in males.
The percentage of patients with events suggestive of urinary tract infections was similar across treatment groups, as follows: 4.5% with dapagliflozin 2.5 mg, 7.6% with dapagliflozin 5 mg and 7.9% for dapagliflozin 10 mg compared to 7.5% with placebo added to glimepiride. Overall, events suggestive of urinary tract infections were higher in females than in males.
No kidney infections were reported in the study.About Type 2 Diabetes In 2011, diabetes was estimated to affect more than 365 million people aged 20-79 worldwide. Because of the aging population and the growing trend of obesity, the prevalence of diabetes is projected to reach more than 550 million by 2030. Type 2 diabetes accounts for approximately 90 to 95% of all cases of diagnosed diabetes in adults. Type 2 diabetes is a chronic, progressive disease characterized by insulin resistance and/or dysfunction of beta cells in the pancreas, which decreases insulin sensitivity and secretion, leading to elevated glucose levels. Over time, this sustained hyperglycemia contributes to worsening insulin resistance and further beta cell dysfunction. To date, treatments for type 2 diabetes have focused primarily on insulin-dependent mechanisms. An approach that acts independently of insulin could provide an additional option for adults with type 2 diabetes.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV